跳至主要内容
临床试验/NCT05202834
NCT05202834已完成不适用

Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on Human Skin

FA Corporation1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2021年7月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
3
试验地点
1
主要终点
Histology Study of Laser Ablation on human skin

研究概览

简要总结

Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on human skin

详细描述

The study is being conducted to evaluate the safety and efficacy of the UltraClear Mid IR Fiber Laser Workstation using both superficial epidermis ablation capabilities and the deep ablative and coagulative capabilities into the dermis. Epidermis is the skin most outer layer that is supported by the dermis, which is the thick layer of living tissue below the epidermis which forms the true skin, containing blood capillaries, nerve endings, sweat glands, hair follicles, and other structures. Superficial ablative properties of the laser are the ability to remove thin and controlled layer of epidermis without damaging the underlaying layers of the skin, while the deep ablative properties of the laser are the ability to create a controlled and consistent mechanical and thermal injury in the skin that will lead to strong healing process that will improve the skin properties such as softness, elasticity and appearance. Round ø4.0 mm ( ~ø 1/8") Biopsies will be taken to examine the histologic effects of the treatments.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Fitzpatrick skin type I-VI.
  • Male or female.
  • Subjects must be between 25 and 75 years of age.
  • Subjects must have ability to get treatment and biopsy from tissue in the abdomen or Buttock.
  • Subjects must read, understand, and sign the Informed Consent.
  • Subjects must be willing and able to comply with all follow-up requirements.

排除标准

  • Subjects must not have active localized or systemic infections.
  • Lidocaine or epinephrine allergy.
  • Subjects must not have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease (e.g. lupus, scleroderma, history of keloid scar formation), atrophic dermatitis or immunologic abnormalities such as vitiligo.
  • Subjects must not have had treatments with 5FU, hydroquinone, diclofenac, imiquimod, retinoids, or PDT within one month prior to enrollment.
  • Subjects must not currently be taking Accutane, or have taken Accutane within the last 6 months.
  • Subjects must not have a known allergy to the following topical products: lidocaine (numbing cream).
  • Subject must not have used topical steroids or retinoids within the last 3 months on treatment surfaces.
  • Subjects must not have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia.
  • Subjects must agree to refrain from using cosmeceutical agents or topical agents during the course of the study, except as directed by study investigators.
  • Subjects must not be pregnant or breastfeeding.
  • Active sunburn or excessively tanned skin

结局指标

主要结局

Histology Study of Laser Ablation on human skin

时间窗: Immediate after treatment

Histological specimens microscope ready slides

次要结局

未报告次要终点

研究者

发起方
FA Corporation
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验